| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MAP2K1; MEK1; PRKMK1; Dual specificity mitogen-activated protein kinase kinase 1; MAP kinase kinase 1; MAPKK 1; MKK1; ERK activator kinase 1; MAPK/ERK kinase 1; MEK 1 |
| Entrez GeneID | 5604 |
| WB Predicted band size | Calculated MW: 43 kDa; Observed MW: 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human MEK1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于MEK1抗体的参考文献(模拟示例，实际引用请核实原文)：
1. **"A highly specific monoclonal antibody for detecting endogenous MEK1 in human tissues"**
- 作者：Smith J. et al.
- 摘要：开发了一种高特异性单克隆抗体，用于检测人组织中的MEK1蛋白，验证了其在Western blot和免疫组化中的灵敏度与特异性，为MAPK/ERK信号通路研究提供工具。
2. **"MEK1 phosphorylation status as a biomarker in BRAF-mutant melanoma"**
- 作者：Lee C. et al.
- 摘要：利用MEK1磷酸化特异性抗体分析黑色素瘤患者样本，发现MEK1激活状态与BRAF抑制剂治疗响应相关，提示其作为临床预后的潜在标志物。
3. **"Antibody-based inhibition of MEK1 suppresses tumor growth in colorectal cancer models"**
- 作者：Zhang R. et al.
- 摘要：研究了一种阻断MEK1激酶活性的功能性抗体，在结直肠癌小鼠模型中显示显著抑制肿瘤进展，机制涉及下调ERK信号通路。
(注：以上内容为模拟生成，实际文献需通过PubMed或学术数据库检索确认。)
MEK1 (Mitogen-Activated Protein Kinase Kinase 1), also known as MAP2K1. is a critical serine/threonine kinase in the RAS/RAF/MEK/ERK signaling pathway, which regulates cell proliferation, differentiation, survival, and apoptosis. As a dual-specificity kinase, MEK1 is activated by RAF-mediated phosphorylation and subsequently phosphorylates ERK1/2. transmitting extracellular signals (e.g., growth factors, cytokines) to downstream targets. Dysregulation of MEK1. often through mutations (e.g., P124S, Q56P) or pathway hyperactivation, is implicated in cancers, including melanoma, lung, and pancreatic cancers.
MEK1 antibodies are essential tools for studying its expression, phosphorylation status, and interactions in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess MEK1 levels or activation in tissues and cell lines. Phospho-specific MEK1 antibodies detect phosphorylated residues (e.g., Ser217/221), providing insights into pathway activity. Researchers also employ MEK1 antibodies to explore resistance mechanisms to targeted therapies, such as MEK inhibitors (e.g., trametinib), and to validate the efficacy of experimental drugs. Additionally, they aid in identifying MEK1 mutations in clinical samples, supporting personalized treatment strategies. Due to its central role in oncogenesis, MEK1 remains a key focus in cancer research and therapeutic development.
×
